Akston Biosciences Corporation Revenue and Competitors
Estimated Revenue & Valuation
- Akston Biosciences Corporation's estimated annual revenue is currently $11.3M per year.
- Akston Biosciences Corporation's estimated revenue per employee is $155,000
Employee Data
- Akston Biosciences Corporation has 73 Employees.
- Akston Biosciences Corporation grew their employee count by 49% last year.
Akston Biosciences Corporation's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Quality Control Manager | Reveal Email/Phone |
2 | Manager Quality Control EM and Material Control | Reveal Email/Phone |
3 | Manager, Downstream Process Development | Reveal Email/Phone |
4 | Quality Control Scientist 1 | Reveal Email/Phone |
5 | Quality Assurance Associate I | Reveal Email/Phone |
6 | Staff Engineer Cell Culture Process Development | Reveal Email/Phone |
7 | Scientist II | Reveal Email/Phone |
8 | Manager-Veterinary and Pharmacology Projects | Reveal Email/Phone |
9 | Quantitative Bioanalytics Scientist | Reveal Email/Phone |
10 | Senior Research Associate | Reveal Email/Phone |
Akston Biosciences Corporation Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 1 | -50% | N/A | N/A |
#3 | $5.1M | 33 | 22% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 2 | -60% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | N/A | 11 | 10% | N/A | N/A |
#10 | $5.4M | 29 | 0% | N/A | N/A |
What Is Akston Biosciences Corporation?
Akston Biosciences Corporation is a leader in the field of insulin engineering. The company was founded in 2011 by the former SmartCells, Inc. team who developed the world’s first clinical glucose-responsive insulin (acquired by Merck & Co. in 2010). Combining its core expertise with modern biotechnology manufacturing techniques, Akston is developing new classes of biologic therapeutics for use in autoimmune Type 1 diabetes prevention, ultra-long acting insulin therapy, and oncology to dramatically improve both human and animal health. The company has raised over $18 million in equity financing from the management team and private investors, as well as $10 million from the NIH and the Helmsley Charitable Trust.
keywords:N/A
N/A
Total Funding
73
Number of Employees
$11.3M
Revenue (est)
49%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Beverly
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 76 | -17% | N/A |
#2 | $19.1M | 76 | 23% | N/A |
#3 | $11.9M | 77 | 10% | N/A |
#4 | $19.4M | 77 | 8% | N/A |
#5 | $15M | 89 | -3% | N/A |